← Back to Search

Checkpoint Inhibitor

Nivolumab for Eye Melanoma

Phase 2

Waitlist Available

Led By Suthee Rapisuwon, MD

Research Sponsored by Suthee Rapisuwon

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months

Awards & highlights

Study Summary

This trial is testing a combination of two drugs, nivolumab and ipilimumab, to see if they are effective in treating ocular melanoma.

Eligible Conditions

Eye Melanoma
Melanoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

3 year Relapse Free Survival (RFS)

Secondary outcome measures

3 year OS

Assess Adverse Events

Median RFS

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Nivolumab and IpilimumabExperimental Treatment2 Interventions

All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nivolumab

FDA approved

Ipilimumab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Suthee RapisuwonLead Sponsor

Bristol-Myers SquibbIndustry Sponsor

2,641 Previous Clinical Trials

4,130,012 Total Patients Enrolled

Suthee Rapisuwon, MD5.01 ReviewsPrincipal Investigator - Georgetown University

Hoosier Cancer Research Network

1 Previous Clinical Trials

14 Total Patients Enrolled

5Patient Review

Dr. Smith is an excellent oncologist/hematologist. He is constantly conducting research to ensure that he is providing his patients with the most up-to-date treatments. I am stage IV metastatic kidney carcinoma, and he has been a huge support throughout my journey. I am truly blessed to have him as my doctor.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there multiple sites where this clinical trial is currently being conducted in the state?

"This trial is enrolling patients in 6 distinct regions, including Georgetown University (Washington), the University of California San Francisco and Columbia University (New york). Additionally, there are 3 other sites accepting participants."

Answered by AI

How many volunteers have enrolled in this clinical experiment?

"At the present moment, this clinical trial is not accepting any new participants. Initially posted on July 26th 2018 and most recently edited August 31st 2022, there are presently 754 trials recruiting individuals with melanoma and 765 studies aimed at Ipilimumab therapies actively looking for enrollees."

Answered by AI

To what extent have previous examinations delved into the efficacy of Ipilimumab?

"The initial studies of ipilimumab were conducted at Texas Children's Hospital in 2009. As of now, 365 research projects have been completed while 765 more are still ongoing with many being held in Washington D.C.."

Answered by AI

To what ailments has Ipilimumab been employed therapeutically?

"Ipilimumab has proven efficacious in the treatment of pre-existing anti-angiogenic therapy, malignant neoplasms and unresectable melanoma."

Answered by AI

Are there any vacancies for study participants in this research?

"This investigation is no longer accepting applicants. It was originally published on July 26th 2018 and last edited on August 31st 2022. Alternately, there are 754 separate trials for melanoma patients seeking to enroll new participants and 765 studies involving Ipilimumab that still require volunteers."

Answered by AI

What safety measures must be taken when administering ipilimumab to individuals?

"Based on available research, our team at Power rated the safety of Ipilimumab a 2 as it is only in Phase 2 trials and there are no studies yet to attest to its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Suthee Rapisuwon 2018. "Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03528408.